生物技术公司Entrada Therapeutics Inc(TRDA)宣布其临床研究计划正稳步推进。根据最新时间表,公司将在2026年第二季度公布Elevate-44-201试验首组患者的研究数据,并于2026年年中发布Elevate-45-201试验的首组数据。这两项关键临床数据的披露将为企业后续研发决策提供重要依据。
生物技术公司Entrada Therapeutics Inc(TRDA)宣布其临床研究计划正稳步推进。根据最新时间表,公司将在2026年第二季度公布Elevate-44-201试验首组患者的研究数据,并于2026年年中发布Elevate-45-201试验的首组数据。这两项关键临床数据的披露将为企业后续研发决策提供重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.